A practical perspective on ulcerative colitis: Patients' needs from aminosalicylate therapies

Inflammatory Bowel Diseases

Volumn 12, Issue 12, 2006, Pages 1107-1113

  Loftus Jr , Edward V ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Aminosalicylate; Compliance; Patient satisfaction; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; AZULFIDINE EN TABS; BALSALAZIDE; CORTICOSTEROID; MESALAZINE; OLSALAZINE; SALAZOSULFAPYRIDINE; SPD 476;

ADULT; ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEVER; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HUMAN; INTERNET; LIFESTYLE; MAJOR CLINICAL STUDY; MUSCLE CRAMP; NAUSEA; PATIENT COMPLIANCE; PATIENT SATISFACTION; PILL; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REMISSION; SOCIAL BEHAVIOR; ULCERATIVE COLITIS;

ADULT; AGED; AMINOSALICYLIC ACIDS; CHILD; COLITIS, ULCERATIVE; DEMOGRAPHY; HEALTH SURVEYS; HUMANS; LIFE STYLE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUESTIONNAIRES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 33751574430     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.mib.0000235831.01682.8d     Document Type: Article

References (29)

1. Casellas F, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis. 2005;11:488-496.
2. Saibeni S, Cortinovis I, Beretta L, et al. Gender and disease activity influence health-related quality of life in inflammatory bowel diseases. Hepatogastroenterology. 2005;52:509-515.
3. Janke KH, Klump B, Gregor M, et al. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:272-286.
4. Bernklev T, Jahnsen J, Aadland E, et al. Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis. Scand J Gastroenterol. 2004;39:365-373.
5. Rubin GP, Hungin AP, Chinn DJ, et al. Quality of life in patients with established inflammatory bowel disease: a UK general practice survey. Aliment Pharmacol Ther. 2004;19:529-535.
6. Hjortswang H, Jarnerot G, Curman B, et al. The influence of demographic and disease-related factors on health-related quality of life in patients with ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15:1011-1020.
7. Han SW, McColl E, Barton JR, et al. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis. 2005;11:24-34.
8. Karlinger K, Gyorke T, Mako E, et al. The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol. 2000;35:154-167.
9. Bjornsson S, Johannsson JH. Inflammatory bowel disease in Iceland, 1990-1994: a prospective, nationwide, epidemiological study. Eur J Gastroenterol Hepatol. 2000;12:31-38.
10. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000;46:336-343.
11. Wiercinska-Drapalo A, Jaroszewicz J, Flisiak R, et al. Epidemiological characteristics of inflammatory bowel disease in North-Eastern Poland. World J Gastroenterol. 2005;11:2630-2633.
12. Reddy SI, Burakoff R. Inflammatory bowel disease in African Americans. Inflamm Bowel Dis. 2003;9:380-385.
13. Ogunbi SO, Ransom JA, Sullivan K, et al. Inflammatory bowel disease in African-American children living in Georgia. J Pediatr. 1998;133:103-107.
14. Basu D, Lopez I, Kulkarni A, et al. Impact of race and ethnicity on inflammatory bowel disease. Am J Gastroenterol. 2005;100:2254-2261.
15. Papadakis KA. Diagnosis and misdiagnosis of inflammatory bowel disease. Gastrointest Endosc Clin North Am. 2002;12:433-439.
16. Miniello S, Testini M, Piccinni G, et al. The uncertain primary diagnosis of inflammatory bowel diseases. Panminerva Med. 2002;44:233-236.
17. Farmer M, Petras RE, Hunt LE, et al. The importance of diagnostic accuracy in colonic inflammatory bowel disease. Am J Gastroenterol. 2000;95:3184-3188.
18. Gregor JC, McDonald JWD, Klar N, et al. An evaluation of utility measurement in Crohn's Disease. Inflamm Bowel Dis. 1997;3:265-276.
19. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18(Suppl 2):1-5.
20. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis. 2005;11:421-427.
21. Hanauer SB, Sninsky CA, Robinson M, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. Ann Intern Med. 1996;124:204-211.
22. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2003; CD000543;
23. Sutherland L, Roth D, Beck P, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2002; CD000544;
24. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929-2933.
25. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39-43.
26. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:191-198.
27. Hanauer S, Sandborn W, Kornbluth A, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablet) versus 2.4 g/day (400 mg tablet) for treatment of moderately active ulcerative colitis: combined analysis of two randomised, double-blind, controlled trials (abstract). Gastroenterology. 2005;128:A-74-A-75.
28. Lichtenstein G, Kamm M, Sandborn WJ, et al. SPD476 is a novel, once-daily, high-dose, effective and well tolerated 5ASA formulation for the induction of remission of mild-to-moderate ulcerative colitis: a phase III study [Abstract]. Am J Gastroenterol. 2005;100(9 Suppl):S291-S292.
29. Kamm M, Sandborn WJ, Gassull M, et al. Comparison of the efficacy and safety of SPD476, a novel, once-daily, high dose formulation of mesalamine, and Asacol with placebo for the induction of remission of mild-moderate ulcerative colitis: a phase III study [Abstract]. Am J Gastroenterol. 2005;100(9 Suppl):S291.